Cat. No.: HY-50856

Ruxolitinib

Name: Ruxolitinib
Brand: MedChemExpress
SKU: HY-50856
Price: 72.00 USD
Availability: InStock
Rating: 5 (281 reviews)

(Synonyms: INCB18424)

281 Cited Publications

Avis client

Based on 281 publication(s) in Google Scholar

Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté : 99.95%
CAS No.: 941678-49-5
Formule: C₁₇H₁₈N₆
Masse moléculaire:306.37

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ruxolitinib Chemical Structure

CAS No.: 941678-49-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (281)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole (5)
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Ruxolitinib (INCB18424) is an orally active and selective JAK1/2 inhibitor with IC₅₀s of 3.3 nM and 2.8 nM in cell-free assays, and has 130-fold selectivity for JAK1/2 over JAK3^[1]. Ruxolitinib induces autophagy and kills tumor cells through toxic mitophagy^[3].

IC₅₀ & Target

^[1]

JAK2

2.8 nM (IC₅₀)

JAK1

3.3 nM (IC₅₀)

Tyk2

19 nM (IC₅₀)

JAK3

428 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform JAK :

Cellular Effect

Cell Line	Type	Value	Description	References
BaF3	EC₅₀	186 nM Compound: 1	Inhibition of JAK2 V617F mutant expressed in mouse BaF3 cells cells assessed as reduction in cell viability Inhibition of JAK2 V617F mutant expressed in mouse BaF3 cells cells assessed as reduction in cell viability	[PMID: 27555284]
BaF3	IC₅₀	126 nM Compound: 8	Cytotoxicity against mouse BAF3 cells expressing JAK2 V617F mutant after 48 hrs by CellTiterGlo assay Cytotoxicity against mouse BAF3 cells expressing JAK2 V617F mutant after 48 hrs by CellTiterGlo assay	10.1039/C1MD00175B
HCT-116	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28953386]
HCT-116	IC₅₀	>10 μM Compound: 3	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 29945795]
HEL	IC₅₀	2.62 μM Compound: Ruxolitinib	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant after 48 hrs by MTT assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant after 48 hrs by MTT assay	[PMID: 27774135]
HEL	IC₅₀	0.3 μM Compound: 1	Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay Synergistic antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay	[PMID: 30901208]
HEL	IC₅₀	18.6 μM Compound: 1	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
HEL	IC₅₀	7.639 μM Compound: 1	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant measured after 3 days by CCK8 assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant measured after 3 days by CCK8 assay	[PMID: 30981578]
HEL	IC₅₀	1.4 μM Compound: INCB018424	Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
HEL	IC₅₀	7.46 μM Compound: Ruxolitinib	Cytotoxicity against HEL cells assessed as inhibition of cell growth Cytotoxicity against HEL cells assessed as inhibition of cell growth	[PMID: 36805946]
HEL	IC₅₀	>100 nM Compound: 8	Inhibition of JAK-mediated STAT5 phosphorylation in HEL cells by Western blotting analysis Inhibition of JAK-mediated STAT5 phosphorylation in HEL cells by Western blotting analysis	10.1039/C1MD00175B
HEL 92.1.7	IC₅₀	>4 μM Compound: Ruxolitinib	Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay	[PMID: 27541357]
HEL 92.1.7	IC₅₀	14.7 μM Compound: 1	Antiproliferative activity against HEL 92.1.7 cells assessed as viable cells measured after 3 days by WST-1 assay Antiproliferative activity against HEL 92.1.7 cells assessed as viable cells measured after 3 days by WST-1 assay	[PMID: 27555284]
HEL 92.1.7	IC₅₀	>4 μM Compound: 1	Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay	[PMID: 28953386]
HEL 92.1.7	IC₅₀	18.06 μM Compound: Ruxolitinib	Cytotoxicity against human HEL 92.1.7 cells expressing JAK2 assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay Cytotoxicity against human HEL 92.1.7 cells expressing JAK2 assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay	[PMID: 34046625]
HL-60	IC₅₀	>4 μM Compound: Ruxolitinib	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 27541357]
HL-60	IC₅₀	>4 μM Compound: 1	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 28953386]
Jurkat	IC₅₀	>4 μM Compound: Ruxolitinib	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 27541357]
Jurkat	IC₅₀	>4 μM Compound: 1	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 28953386]
Jurkat	IC₅₀	>5 μM Compound: 1	Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
K562	IC₅₀	10.3 μM Compound: Ruxolitinib	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 27774135]
K562	IC₅₀	1.03 μM Compound: 1	Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay Synergistic antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs in presence of SAHA by MTT assay	[PMID: 30901208]
K562	IC₅₀	23.2 μM Compound: 1	Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human K562 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
KMS-12-BM	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human KMS-12-BM cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
MCF7	IC₅₀	>5 μM Compound: Ruxolitinib	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 27774135]
MCF7	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28953386]
MCF7	IC₅₀	>10 μM Compound: 3	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 29945795]
MDA-MB-231	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28953386]
MDA-MB-231	IC₅₀	>10 μM Compound: 3	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 29945795]
MDA-MB-468	IC₅₀	>20 μM Compound: INCB018424	Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-468 cells overexpressing STAT3 assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 33689932]
MOLM-14	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MOLM14 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human MOLM14 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
MOLT-4	IC₅₀	15.8 μM Compound: Ruxolitinib	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 27774135]
MOLT-4	IC₅₀	15.8 μM Compound: 1	Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 48 hrs by MTT assay	[PMID: 30901208]
MV4-11	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human MV4-11 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human MV4-11 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
OPM-2	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay Antiproliferative activity against human OPM2 cells after 48 hrs by CellTiter-Glo luminescent assay	[PMID: 28953386]
PBMC	IC₅₀	40 nM Compound: Ruxolitinib	Inhibition of JAK1 in human PBMC cells assessed as inhibition of IL-6-induced MCP1 secretion Inhibition of JAK1 in human PBMC cells assessed as inhibition of IL-6-induced MCP1 secretion	[PMID: 26927423]
PBMC	IC₅₀	448 nM Compound: Ruxolitinib	Inhibition IL-7-indcued STAT5 phosphorylation in human PBMC cells by flow cytometry Inhibition IL-7-indcued STAT5 phosphorylation in human PBMC cells by flow cytometry	[PMID: 26927423]
PBMC	CC₅₀	>100 μM Compound: 30	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 33539089]
PC-3	IC₅₀	>5 μM Compound: Ruxolitinib	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 27774135]
PC-3	IC₅₀	>10 μM Compound: 1	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28953386]
PC-3	IC₅₀	>10 μM Compound: 3	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 29945795]
Sf21	IC₅₀	19 nM Compound: 2, INCB018424	Inhibition of human TYK2 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay Inhibition of human TYK2 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay	[PMID: 22591402]
Sf21	IC₅₀	2.8 nM Compound: 2, INCB018424	Inhibition of human JAK2 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay Inhibition of human JAK2 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay	[PMID: 22591402]
Sf21	IC₅₀	3.3 nM Compound: 2, INCB018424	Inhibition of human JAK1 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay Inhibition of human JAK1 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay	[PMID: 22591402]
Sf21	IC₅₀	428 nM Compound: 2, INCB018424	Inhibition of human JAK3 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay Inhibition of human JAK3 kinase domain expressed in Sf21 cells using EQEDEPEGDYFEWLE as substrate after 1 hr by HTRF assay	[PMID: 22591402]
Sf21	IC₅₀	0.003 μM Compound: Jakafi	Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method Inhibition of human recombinant JAK2 expressed in Sf21 cells assessed as reduction in Ulight-CAGAGAIETDKEYYTVKD phosphorylation pre-incubated before substrate addition and measured after 60 mins by LANCE detection method	[PMID: 27137359]
Sf21	IC₅₀	4.1 nM Compound: 1	Inhibition of recombinant human C-terminal 6His-tagged JAK2 (808 to end amino acids) expressed in Sf21 cells measured after 1 hr in presence of ATP by TR-FRET assay Inhibition of recombinant human C-terminal 6His-tagged JAK2 (808 to end amino acids) expressed in Sf21 cells measured after 1 hr in presence of ATP by TR-FRET assay	[PMID: 27555284]
Sf21	IC₅₀	2.8 nM Compound: 1	Inhibition of recombinant human N-terminal epitope-tagged JAK2 (828 to 1132 residues) expressed in baculovirus infected Sf21 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by homogeneous time-resolved fluorescence assay Inhibition of recombinant human N-terminal epitope-tagged JAK2 (828 to 1132 residues) expressed in baculovirus infected Sf21 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by homogeneous time-resolved fluorescence assay	[PMID: 30981578]
Sf9	IC₅₀	2.8 nM Compound: 1	Inhibition of human JAK2 (828 to 1132 residues) expressed in baculovirus infected Sf9 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by fluorescence assay Inhibition of human JAK2 (828 to 1132 residues) expressed in baculovirus infected Sf9 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by fluorescence assay	[PMID: 30833158]
Sf9	IC₅₀	3.3 nM Compound: 1	Inhibition of human JAK1 (837 to 1142 residues) expressed in baculovirus infected Sf9 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by fluorescence assay Inhibition of human JAK1 (837 to 1142 residues) expressed in baculovirus infected Sf9 insect cells using EQEDEPEGDYFEWLE as substrate after 1 hr by fluorescence assay	[PMID: 30833158]
Sf9	IC₅₀	0.004 μM Compound: 1	Inhibition of human recombinant N-terminal hexahistidine tagged JAK1 JH1 catalytic domain (854 to 1154 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr Inhibition of human recombinant N-terminal hexahistidine tagged JAK1 JH1 catalytic domain (854 to 1154 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr	[PMID: 30981578]
Sf9	IC₅₀	0.051 μM Compound: 1	Inhibition of human recombinant C-terminal hexahistidine tagged JAK3 JH1 catalytic domain (811 to 1124 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr Inhibition of human recombinant C-terminal hexahistidine tagged JAK3 JH1 catalytic domain (811 to 1124 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr	[PMID: 30981578]
Sf9	IC₅₀	0.0006 μM Compound: 1	Inhibition of human recombinant N-terminal hexahistidine tagged JAK2 JH1 catalytic domain (835 to 1132 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr Inhibition of human recombinant N-terminal hexahistidine tagged JAK2 JH1 catalytic domain (835 to 1132 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr	[PMID: 30981578]
Sf9	IC₅₀	0.6 nM Compound: 1	Inhibition of human recombinant N-terminal hexahistidine tagged JAK2 JH1 catalytic domain (835 to 1132 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr Inhibition of human recombinant N-terminal hexahistidine tagged JAK2 JH1 catalytic domain (835 to 1132 residues) expressed in baculovirus infected Sf9 cells using Tyr6 peptide as substrate incubated for 30 secs under shaking condition measured after 1 hr	[PMID: 30981578]
T-cell	IC₅₀	0.023 μM Compound: 1b	Inhibition of JAK3/1 in human T cells expressing CD3 assessed as inhibition of IL2-stimulated STAT5a phosphorylation Inhibition of JAK3/1 in human T cells expressing CD3 assessed as inhibition of IL2-stimulated STAT5a phosphorylation	[PMID: 23540648]
T-cell	IC₅₀	0.031 μM Compound: 1b	Inhibition of JAK2/1 in human T cells expressing CD3 assessed as inhibition of IFNgamma-stimulated STAT1 phosphorylation Inhibition of JAK2/1 in human T cells expressing CD3 assessed as inhibition of IFNgamma-stimulated STAT1 phosphorylation	[PMID: 23540648]
TF-1	EC₅₀	12 nM Compound: 2, INCB018424	Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins prior to EPO-induction measured after 30 to 45 mins Inhibition of JAK2 in human TF1 cells assessed as inhibition of EPO-induced STAT5 phosphorylation incubated for 20 mins prior to EPO-induction measured after 30 to 45 mins	[PMID: 22698084]
TF-1	EC₅₀	24 nM Compound: 2, INCB018424	Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins prior to IL6-induction measured after 30 to 45 mins Inhibition of JAK1 in human TF1 cells assessed as inhibition of IL6-induced STAT3 phosphorylation incubated for 20 mins prior to IL6-induction measured after 30 to 45 mins	[PMID: 22698084]
TF-1	IC₅₀	6.85 nM Compound: Ruxolitinib	Inhibition of JAK2 in human TF1 cells assessed as reduction in STAT5 phosphorylation incubated for 30 mins in presence of human recombinant EPO Inhibition of JAK2 in human TF1 cells assessed as reduction in STAT5 phosphorylation incubated for 30 mins in presence of human recombinant EPO	[PMID: 23061660]
TF-1	IC₅₀	14.35 μM Compound: Ruxolitinib	Cytotoxicity against human TF-1 cells expressing JAK2 assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay Cytotoxicity against human TF-1 cells expressing JAK2 assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay	[PMID: 34046625]
Vero	IC₅₀	>50 μM Compound: Ruxolitinib	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by presto blue reagent assay	[PMID: 34046625]

In Vitro

Ruxolitinib potently and selectively inhibits JAK2V617F-mediated signaling and proliferation, markedly increases apoptosis in a dose dependent manner, and at 64 nM results in a doubling of cells with depolarized mitochondria in Ba/F3 cells.
Ruxolitinib demonstrates remarkable potency against erythroid colony formation with IC₅₀ of 67 nM, and inhibits proliferating of erythroid progenitors from normal donors and polycythemia vera patients with IC₅₀ values of 407 nM and 223 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

Ruxolitinib (180 mg/kg, orally, twice a day) results in survive rate of greater than 90% by day 22 and markedly reduces splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects in a JAK2V617F-driven mouse model^[1].
In the Ruxolitinib group, the primary end point is reached in 41.9% of patients, as compared with 0.7% in the placebo group in the double-blind trial of myelofibrosis. Ruxolitinib results in maintaining of reduction in spleen volume and improvement of 50% or more in the total symptom score^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 941678-49-5
Appearance Solid
Masse moléculaire 306.37
Formule C₁₇H₁₈N₆
Color White to light yellow
SMILES

N#CC[C@H](C1CCCC1)N2N=CC(C3=C4C=CNC4=NC=N3)=C2
Synonyms

INCB18424
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (281)

All In Vivo Efficacy Study2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayCell Migration/Invasion AssayCell Imaging/StainingRT-PCRFlow CytometryMicrobiological AssayWBIFHistological Imaging/Staining

Sort by:

Journal Impact Factor

N Engl J Med

The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1. [Abstract]

2024 May 30;390(20):1873-1884. PMID: 38810185

Ruxolitinib purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2024 May 30;390(20):1873-1884. [Abstract]

Survival rate analysis among groups of the Pilocarpine (Ruxolitinib phosphate) (300 mg/kg; i.p.)-induced SE model.
Signal Transduct Target Ther

Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. [Abstract]

2024 Mar 9;9(1):65. PMID: 38461173
Cancer Cell

2026 Aug 10;44(8):1639-1652.e6. PMID: 42425075
Nature

Clinical functional proteomics of intercellular signalling in pancreatic cancer. [Abstract]

2025 Jan;637(8046):726-735. PMID: 39537929

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8046):726-735. [Abstract]

Investigation of the signalling axis regulating LIF expression upon PDGF stimulation. Cells were treated with PDGFR inhibitor crenolanib (0.5 μM), JAK inhibitor Ruxolitinib (1 μM), PI3K inhibitor LY294002 (10 μM), PTPN11 inhibitor SHP099 (10 μM), MEK inhibitor mirdametinib (10 μM), or ERK inhibitor ravoxertinib (10 μM) for 24 h before cell lysis for total RNA extraction and measurement of LIF mRNA levels by real-time qPCR.
Nature

Targeting TBK1 to overcome resistance to cancer immunotherapy. [Abstract]

2023 Mar;615(7950):158-167. PMID: 36634707
Nature

Coronaviruses exploit a host cysteine-aspartic protease for replication. [Abstract]

2022 Sep;609(7928):785-792. PMID: 35922005

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):785-792. [Abstract]

Huh7 cells are pretreated with DMSO, 5 μM Filgotinib, 5 μM Ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride for 1 h and infected with MERS-CoV at a MOI of 1. MERS-CoV N gene copy number is quantified by RT-qPCR.
Nat Med

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. [Abstract]

2018 Aug;24(8):1143-1150. PMID: 30038220

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Med. 2018 Aug;24(8):1143-1150. [Abstract]

Immunoblot of pSTAT1, STAT1 and β-actin levels in H69AR cells±200 ng/mL IFNg 10 min pulse followed by 24 h chase in media with DMSO, Ruxolitinib (100 nM) or MRT67307 (1 µM).
J Hematol Oncol

PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia. [Abstract]

2021 Jun 24;14(1):97. PMID: 34167562

Ruxolitinib purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2021 Jun 24;14(1):97. [Abstract]

Growth curves for DND-41, RPMI-8402 and LOUCY T-ALL cell lines. Growth medium was supplemented with DMSO, MRK-560 100 nM, ruxolitinib 1 µM or both compounds.
Science

Antifibrotic drug finerenone restores fertility in premature ovarian insufficiency. [Abstract]

2026 Feb 5;391(6785):eadz4075. PMID: 41643022

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Science. 2026 Feb 5;391(6785):eadz4075. [Abstract]

Anti-fibrotic effects of FDA-approved oral conpound in cultured mouse ovarian fibroblasts. RT–qPCR analysis of fibrosis markers (Col1a1, Col3a1, Acta2) following a 24-hour treatment with Ruxolitinib (1 μM; 24 h). Ruxolitinib significantly suppressed mRNA expression of fibrosis-associated genes.
Cell

Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. [Abstract]

2024 Apr 25;187(9):2288-2304.e27. PMID: 38565142
Cell

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. [Abstract]

2021 Apr 15;184(8):2167-2182.e22. PMID: 33811809
Cancer Discov

Oncogenic KRAS-dependent stromal interleukin-33 directs the pancreatic microenvironment to promote tumor growth. [Abstract]

2024 Oct 4;14(10):1964-1989. PMID: 38958646
Cancer Discov

HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development. [Abstract]

2018 May;8(5):616-631. PMID: 29496663

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 May;8(5):616-631. [Abstract]

Analysis of PIM1 RNA and protein expression in HOXA9 positive patient derived xenograft (PDX) samples ex vivo after 1 μM Ruxolitinib over 6 hours.
Cancer Commun (Lond)

MAGE-C3 promotes cancer metastasis by inducing epithelial-mesenchymal transition and immunosuppression in esophageal squamous cell carcinoma. [Abstract]

2021 Dec;41(12):1354-1372. PMID: 34347390

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Dec;41(12):1354-1372. [Abstract]

The MAGE‐C3 overexpressing KYSE30 cells are treated with Ruxolitinib (2 μM, for 20 h.) and probed for STAT1 expression pSTAT1Tyr701. The pSTAT1Tyr701 expression levels are almost unchanged when exposure to Ruxolitinib in presence with IFN‐γ.
Nat Cancer

Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation. [Abstract]

2025 Sep;6(9):1537-1558. PMID: 40550901

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 Sep;6(9):1537-1558. [Abstract]

Representative images and immunostaining of DMSO, JSH-23 (1 uM) and Ruxolitinib (10 uM) treated prostate organoids from K5-PTEN mice 5 days following TAM administration and quantification of hyperplastic organoids and YFP+K8+ in total YFP+ cells using indicated antibodies. Scale bar, 500 μm (up), 50 μm (down). n=3 independent experiments. The results showed that treatment of these organoids with JSH-23 and Ruxolitinib decreased the proportion of hyperplastic organoids and basal to luminal transition in vitro.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 Sep;6(9):1537-1558. [Abstract]

Representative FACS plot of CD49f and EpCAM expression in YFP+ prostate epithelial cells from DMSO, JSH-23 and Ruxolitinib (10mg/kg; i.p.; 3 times weekly, every other day, for 5 weeks) treated K5-PTEN 6w and K5-PTEN-PIK 3w mice. Ruxolitinib, a JAK1/JAK2 inhibitor, reduced the differentiation of breast carcinoma (BC) into lobular carcinoma (LC) when administered 6 weeks after Pten deletion in BC and 3 weeks following Pten‑Pik3ca targeting in BC.
Nat Cancer

Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. [Abstract]

2022 Sep;3(9):1071-1087. PMID: 36065066

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Sep;3(9):1071-1087. [Abstract]

Relative cell number of LNCaP/AR cells treated with annotated treatment: 10 µM Enzalutamide (Enz), 5 µM Filgotinib (Filg), 5 µM Ruxolitinib (Ruxo), 1 µM Fludarabine (Flu), 0.2 µM Niclosamide (Nic) and DMSO for 8 days.
Nat Biomed Eng

Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence. [Abstract]

2025 Oct 22. PMID: 41125869
Gut

Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. [Abstract]

2020 Jan;69(1):122-132. PMID: 31076405
Ann Rheum Dis

Inhibition of the type I interferon receptor pathway protects against muscle weakness induced by dermatomyositis serum. [Abstract]

2026 Mar 17:S0003-4967(26)00096-8. PMID: 41850941
Ann Rheum Dis

Augmentation of immunothrombosis as a key mechanism underlying JAK inhibition associated hypercoagulability in rheumatoid arthritis. [Abstract]

2025 Sep 25:S0003-4967(25)04383-3. PMID: 41006174
Cell Mol Immunol

Serine metabolism orchestrates macrophage polarization by regulating the IGF1-p38 axis. [Abstract]

2022 Nov;19(11):1263-1278. PMID: 36180780
Cell Mol Immunol

Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression. [Abstract]

2022 Oct;19(10):1130-1140. PMID: 36042351

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

Ruxolitinib (100 mg/kg/day; i.p.; 8 weeks) reduced the expression of proinflammatory cytokine genes in the livers of ARE-Del^+/− mice. RNA is isolated from the livers of Ruxolitinib-treated mice.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

Levels of IL-6, TNF, and MCP1 production in macrophages isolated from wild-type mice (females/20 weeks) following in vitro treatment with Ruxolitinib were determined utilizing CBA and flow cytometry.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

The expression of phosphorylated (p-) and unphosphorylated STAT1 and STAT6 in macrophages is assessed by western blotting. The results demonstrated that pSTAT1 and STAT1 were inhibited in macrophages treated with Ruxolitinib (1-10 μM), while STAT6 was activated concomitantly.
Blood

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. [Abstract]

2014 Dec 18;124(26):3924-31. PMID: 25352124
Blood

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. [Abstract]

2013 Nov 21;122(22):3628-31. PMID: 24081659

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Blood. 2013 Nov 21;122(22):3628-31. [Abstract]

Ruxolitinib decreased spleen weight. Mice were sacrificed on day 21 or 24 to evaluate spleen size.
Cell Stem Cell

Paired pre- and post-transplant human immunoprofiling identifies an IFN-γ-JAK1 axis limiting stem-cell-derived RPE engraftment. [Abstract]

2026 Jul 2;33(7):1127-1143.e10. PMID: 42309064

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

Representative images showing the decreased wound area in the in vitro scratch assay. Ruxolitinib (4 μM; 48 h) pretreatment largely corrected IFN-γ-induced deficits, restoring migration toward control levels.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

Representative flow plots (left) and quantification (right) of apoptosis in hESC-RPE cells treated with vehicle, IFN-γ, Ruxolitinib (4 μM; 48 h) + IFN-γ, or Ruxolitinib (n = 6 technical replicates).

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

Left: representative immunofluorescence images of ZO-1 (red) and DAPI (blue) costaining in hESC-RPE cells treated with vehicle, IFN-γ, Ruxolitinib (4 μM; 48 h) + IFN-γ, or Ruxolitinib. Scale bars, 20 μm. Right: quantification of ZO-1 expression (n = 5 technical replicates).

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

Representative bioluminescence images tracking luciferase+ hESC-RPE graft survival in NPG mice and hu-mice across groups. Unhumanized NPG mice served as immune-deficient controls.43 Luciferase-expressing hESC-RPE cells were pretreated with Ruxolitinib (4 μM) or vehicle for 48 h, transplanted subcutaneously and monitored by serial bioluminescence imaging. The results showed that in hu-mice receiving vehicle-treated hESC-RPE, bioluminescent signal dropped sharply by day 2, whereas Ruxolitinib-pretreated grafts retained higher signal at days 4, 8, and 12. Signal intensities were initially similar between ruxolitinib-pretreated grafts in hu-mice and vehicle-treated grafts in unhumanized NPG mice, with separation emerging by day 8.
Nat Cell Biol

An SP110-SP100 axis is a critical regulator of promyelocytic leukaemia body dynamics and mitotic fidelity. [Abstract]

2026 Mar 13. PMID: 41826696

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2026 Mar 13. [Abstract]

Competition assay comparing the ratio of SP110-KO versus WT cells on day 7 with the indicated treatments. The results showed that chemical inhibition of interferon signalling using Ruxolitinib (20 µM; 72 h) also prevented cell death in SP110-KO cells.
Nat Cell Biol

DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Dec;27(12):2143-2151. PMID: 41249572

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Dec;27(12):2143-2151. [Abstract]

DTEP formation from A375 WT persister cells treated with 250 nM dabrafenib and 25 nM trametinib for 2 weeks followed by the addition of 1 μM JAK inhibitor Ruxolitinib for 5 weeks. The results showed that the cotreatment of persister cells with JAK inhibitor Ruxolitinib to block IFN signalling increased the proportion of persister cells which regrew into DTEP colonies.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Dec;27(12):2143-2151. [Abstract]

DTEP formation from PC9 persister cells co-treated with 300 nM osimertinib and 5 μM ruxolitinib for 5 weeks. The results showed that the cotreatment of persister cells with JAK inhibitor Ruxolitinib to block IFN signalling increased the proportion of persister cells which regrew into DTEP colonies.
Cancer Res

2026 Jul 23. PMID: 42489533
Cancer Res

JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States. [Abstract]

2023 Jan 18;83(2):264-284. PMID: 36409824

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Jan 18;83(2):264-284. [Abstract]

Graphs depicting SUM149 (top) and SUM190 (bottom) xenograft tumor volume in mice treated with vehicle, paclitaxel (PTX), Ruxolitinib (RUX) (60 mg/kg/day and delivered by subcutaneous osmotic pumps), or the combination, with green arrow depicting treatment start when tumors were first palpable (∼20 mm³ for SUM149 and ∼60 mm³ for SUM190).

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Jan 18;83(2):264-284. [Abstract]

Immunoblot analysis of pSTAT3 and STAT3 in xenografts. ACTB was used as a loading control. Dot plot depicts quantification of pSTAT3/STAT3 ratios. The results showed that Ruxolitinib (RUX, 60 mg/kg/day and delivered by subcutaneous osmotic pumps) significantly decreased pSTAT3 levels in SUM190 xenografts, and while we saw a similar trend in SUM149, these tumors tended to be heterogeneous for pSTAT3.
Drug Resist Updat

2026 Feb 8;86:101375.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

Ruxolitinib (JAK/STAT inhibitor, 10 μM; 24 h) prevented Rnf26 upregulation at day 7 in 3D co-culture (qRT‑PCR).

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

Ruxolitinib (60 mg/kg; oral gavage; twice daily) suppressed tumor growth in HBC transgenic mice.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

Ruxolitinib (60 mg/kg; oral gavage; twice daily) reduced RNF26 expression and enhanced CD3⁺ T cell infiltration in HBC transgenic mice.
Adv Funct Mater

2025 Apr 21.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Apr 21.

Cell viability and mRNA transfection efficiency by HEK293T cells concurrently treated with 0, 0.2, 0.5, 1, 2, 5, 10, 20, or 50 μM of Ruxolitinib and Luciferase-mRNA/LNP for 24 h (n = 5–6)
Nat Commun

Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]

2026 Feb 12;17(1):1214. PMID: 41680175
Nat Commun

An inherited mitochondrial DNA mutation remodels inflammatory cytokine responses in macrophages and in vivo in mice. [Abstract]

2025 Nov 20;16(1):10222. PMID: 41266309

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 20;16(1):10222. [Abstract]

COX2 and pro-IL-1β protein levels in non-stim and LPS-stimulated WT and m.5019A>G BMDMs treated with Ruxolitinib (1 μM; 1 h) or vehicle control Ab (n = 3; LPS 6 h). Representative blot shown.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 20;16(1):10222. [Abstract]

Inducible nitric oxide synthase (iNOS) protein levels in non-stim and LPS-stimulated WT and m.5019A>G BMDMs treated with Ruxolitinib (1 μM; 1 h) or vehicle control Ab (n = 3; LPS 24 h). Representative blot shown.
Nat Commun

A loss-of-function human ADAR variant activates innate immune response and promotes bowel inflammation. [Abstract]

2025 Sep 29;16(1):8560. PMID: 41022715

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

Representative images and Caspase 3/7 activity (green) and PI (red) staining of organoids isolated from the ileum of Villin-CreERT2 Adar^fl/fl mice and treated without or with 4-OHT (200 nM) and co-treated with 1 μM Ruxolitinib (Rux), Tofacitinib (Tof), Fedratinib (Fed), or Itacitinib (Ita) for 5 days. Scale bars: 100 μm. The results showed that the JAK1/2 dual inhibitor Ruxolitinib showed the best efficacy in rescuing Adar deficiency-induced organoid death, whereas the JAK1 inhibitor Itacitinib, JAK2 inhibitor Fedratinib, and JAK3/2 inhibitor Tofacitinib were not effective.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

Representative images of the growth process of organoids isolated from the ileumof Villin-CreERT2 Adar^fl/fl mice and treated without or with 4-OHT (200 nM) and co-treated with 1μMRuxolitinib (Rux), Tofacitinib (Tof), Fedratinib (Fed), or Itacitinib (Ita) for 5 days. The results showed that the JAK1/2 dual inhibitor Ruxolitinib showed the best efficacy in rescuing Adar deficiency-induced organoid death, whereas the JAK1 inhibitor Itacitinib, JAK2 inhibitor Fedratinib, and JAK3/2 inhibitor Tofacitinib were not effective.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

Survival curves of Adar^fl/fl and TMX induced AdariΔgut mice co-treated with Ruxolitinib (Rux) (60 mg/kg/day), Tof (40 mg/kg/day), Fed (60 mg/kg/day), or Ita (30 mg/kg/day) by daily i.p. injections for 5 days. The results showed Ruxolitinib, but not other JAK inhibitors, showed the best effect in preventing Adar ablation induced animal death.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

H&E staining of intestine and colon sections. Scale bars: 100 μm. Adar^fl/fl and TMX induced AdariΔgut mice co-treated with Ruxolitinib (Rux) (60 mg/kg/day), Tof (40 mg/kg/day), Fed (60 mg/kg/day), or Ita (30 mg/kg/day) by daily i.p. injections for 5 days. The results showed that Ruxolitinib, but not other JAK inhibitors, showed the best effect in preventing Adar ablation-induced mucosal epithelial damage.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

Immunofluorescence of E-cadherin (red), Lysozyme (green) and Muc2 (red). Scale bars: 100 μm. The results showed that Ruxolitinib (Rux) (60 mg/kg/day; i.p.; once daily for 5 days) caused a loss of E-cadherin and Muc2 expression in Adar^iΔgut mice mice.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

Western blot analysis of ileal samples. The relative values of protein expression are labeled (n = 3). The results showed that Ruxolitinib (Rux) (60 mg/kg/day; i.p.; once daily for 5 days) caused a loss of E-cadherin and Muc2 expression and increased expression of cleaved caspase 3 and p-Stat1 in Adar^iΔgut mice.
Nat Commun

Unveiling genetic signatures of immune response in immune-related diseases through single-cell eQTL analysis across diverse conditions. [Abstract]

2025 Aug 4;16(1):7134. PMID: 40759647
Nat Commun

Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers. [Abstract]

2025 Jul 29;16(1):6972. PMID: 40730818

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 29;16(1):6972. [Abstract]

Cell survival of SUM149 BRCA1-Mut and BRCA1-Rev cells transfected with a concentration range (nM) of ADAR1 siRNA in the context of exposure to the JAK/STAT pathway inhibitors (JSPi) Ruxolitinib (10 µM; 5 days).
Nat Commun

JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms. [Abstract]

2025 Jul 8;16(1):6270. PMID: 40623967

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 8;16(1):6270. [Abstract]

Western blot for the indicated proteins in HEL cells expressing GFP, Empty or NRAS^Q61K vectors, treated 24 h with Ruxolitinib (3 µM). Ruxolitinib treatment for 24 h resulted in decreased ERK phosphorylation in a RAS WT context.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 8;16(1):6270. [Abstract]

Percentage of GFP+ and GFP−_Empty or GFP−_NRAS^Q61K HEL or UKE-1 cells. 24 days after Ruxolitinib (3 µM and 15 µM for HEL and UKE-1, respectively), the indicated cells were treated 3 days with Ruxolitinib or Ruxolitinib (Ruxo.) and trametinib (Trame.) (10 µM and 0.1 µM for HEL and UKE-1, respectively) (n = 3 biological replicates). The results showed that trametinib treatment partially reverted the Ruxolitinib-induced NRAS^Q61K cellular fitness increase, suggesting that the MAPK pathway inhibition re-sensitizes NRAS^Q61K cells to Ruxolitinib.
Nat Commun

Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade. [Abstract]

2024 Aug 26;15(1):7165. PMID: 39187481
Nat Commun

Heterozygous de novo dominant negative mutation of REXO2 results in interferonopathy. [Abstract]

2024 Aug 6;15(1):6685. PMID: 39107301
Nat Commun

ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. [Abstract]

2024 Jan 10;15(1):446. PMID: 38199985
Nat Commun

Skin basal cell carcinomas assemble a pro-tumorigenic spatially organized and self-propagating Trem2+ myeloid niche. [Abstract]

2023 May 10;14(1):2685. PMID: 37164949
Nat Commun

TMEM25 inhibits monomeric EGFR-mediated STAT3 activation in basal state to suppress triple-negative breast cancer progression. [Abstract]

2023 Apr 24;14(1):2342. PMID: 37095176
Nat Commun

Genotoxic stress and viral infection induce transient expression of APOBEC3A and pro-inflammatory genes through two distinct pathways. [Abstract]

2021 Aug 13;12(1):4917. PMID: 34389714

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 13;12(1):4917. [Abstract]

The A3A mRNA level is monitored in MCF10A cells 16 h after treatment with 3p-hpRNA and JAK inhibitors (JAKi #1: 2 μM Pacritinib, JAKi #2: 2 μM Ruxolitinib).
Int J Oral Sci

Loss of tricellular tight junction tricellulin leads to hyposalivation in Sjögren's syndrome. [Abstract]

2025 Mar 19;17(1):22. PMID: 40108118
J Adv Res

Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway. [Abstract]

2023 May:47:151-162. PMID: 35842187
Sci Immunol

Initiator cell death event induced by SARS-CoV-2 in the human airway epithelium. [Abstract]

2024 Jul 12;9(97):eadn0178. PMID: 38996010
Mol Cell

2026 Aug 6;86(15):2950-2965.e9. PMID: 42480521
Nat Chem Biol

PSAT1 impairs ferroptosis and reduces immunotherapy efficacy via GPX4 hydroxylation. [Abstract]

2025 Apr 25. PMID: 40281343
Sci Transl Med

Differentiation of crescent-forming kidney progenitor cells into podocytes attenuates severe glomerulonephritis in mice. [Abstract]

2022 Aug 10;14(657):eabg3277. PMID: 35947676
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Theranostics

ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition. [Abstract]

2022 Oct 3;12(16):7051-7066. PMID: 36276640

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Oct 3;12(16):7051-7066. [Abstract]

A549 cells were treated with 2.5 µM BVD and 10 µM Ruxolitinib (Rux) separately or in combination for 2 days. Immunoblotting was conducted to determine pSTAT3-Y705.
Genes Dis

2026 Jun 11.
J Clin Invest

Osimertinib activates a TGFβ2-dependent secretory program that drives lung adenocarcinoma progression. [Abstract]

2025 Dec 9:e198418. PMID: 41364502
J Exp Clin Cancer Res

Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis. [Abstract]

2025 Jun 5;44(1):172. PMID: 40474298
J Clin Invest

Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. [Abstract]

2021 Dec 15;131(24):e145501. PMID: 34730109
Adv Sci (Weinh)

Mitochondrial Damage-Induced Innate Immune Activation in Vascular Smooth Muscle Cells Promotes Chronic Kidney Disease-Associated Plaque Vulnerability. [Abstract]

2021 Jan 6;8(5):2002738. PMID: 33717842
Cell Rep Med

HE4 drives PD-L1 expression in myeloid cells via IFN-γR-JAK-STAT3 signaling to promote tumor immune evasion. [Abstract]

2026 Apr 21;7(4):102691. PMID: 41861828
Cell Rep Med

A glucocorticoid spike derails muscle repair to heterotopic ossification after spinal cord injury. [Abstract]

2024 Dec 17;5(12):101849. PMID: 39657663
Cell Rep Med

STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma. [Abstract]

2024 Mar 19;5(3):101472. PMID: 38508140
Sci Adv

VAPB is a negative regulator of STING-mediated innate immune signaling. [Abstract]

2025 Dec 5;11(49):eaea3996. PMID: 41337593
Sci Adv

Epitranscriptomic m5C methylation of SARS-CoV-2 RNA regulates viral replication and the virulence of progeny viruses in the new infection. [Abstract]

2024 Aug 9;10(32):eadn9519. PMID: 39110796
Sci Adv

JAK/STAT signaling pathway affects CCR5 expression in human CD4+ T cells. [Abstract]

2024 Mar 22;10(12):eadl0368. PMID: 38507500
Mol Biomed

Telocyte-derived exosomes promote angiogenesis and alleviate acute respiratory distress syndrome via JAK/STAT-miR-221-E2F2 axis. [Abstract]

2025 Apr 8;6(1):21. PMID: 40198510
Cell Death Dis

p53-loss induced prostatic epithelial cell plasticity and invasion is driven by a crosstalk with the tumor microenvironment. [Abstract]

2025 Jan 26;16(1):46. PMID: 39865080
Cell Mol Biol Lett

IP3R1-mediated MAMs formation contributes to mechanical trauma-induced hepatic injury and the protective effect of melatonin. [Abstract]

2024 Feb 2;29(1):22. PMID: 38308199
Cell Death Dis

Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma. [Abstract]

2022 May 25;13(5):496. PMID: 35614034

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 May 25;13(5):496. [Abstract]

The xenografts treated with both Trametinib and Ruxolitinib (20 mg/kg; i.p.; every 3 days) show the expression of pSTAT3 and pERK1/2 in xenograft tumors exposed to the indicated treatment. Densitometry analyses of pSTAT3 and pERK1/2 expression normalized to STAT3 and ERK1/2 expression, respectively.
Cell Death Dis

A small natural molecule CADPE kills residual colorectal cancer cells by inhibiting key transcription factors and translation initiation factors. [Abstract]

2020 Nov 15;11(11):982. PMID: 33191401
J Immunother Cancer

Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. [Abstract]

2025 May 11;13(5):e010831. PMID: 40350206
J Exp Med

TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition. [Abstract]

2024 Jul 1;221(7):e20240111. PMID: 38805014
J Exp Med

TCR signaling induces STAT3 phosphorylation to promote TH17 cell differentiation. [Abstract]

2024 Mar 4;221(3):e20230683. PMID: 38324068
J Exp Med

EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. [Abstract]

2024 Mar 4;221(3):e20232028. PMID: 38284990
Phytomedicine

Diosmetin alleviates the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma by dually inhibiting angiogenesis and promoting CD8+T cell cytotoxicity. [Abstract]

2026 May:154:158036. PMID: 41830859
Hemasphere

AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms. [Abstract]

2021 Aug 11;5(9):e630. PMID: 34396051
Adv Healthc Mater

Ionic Liquid-Mediated Delivery of Ruxolitinib to Skin Using an Adhesive Topical Hydrogel System. [Abstract]

2025 Jul 22:e01838. PMID: 40693314
Clin Cancer Res

STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair. [Abstract]

2018 Apr 15;24(8):1917-1931. PMID: 29483142

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. [Abstract]

Jak2 is inhibited by lentiviral expression of Jak2 shRNA or control shRNA in CWR22Pc and CWR22Rv1 cells. Alternatively, cells are treated with Jak2 inhibitors AZD1480 (0.8 μM) and Ruxolitinib (0.4 μM) (72 h), followed by Western blot analysis of Jak2 and active Stat5a/b.
Cell Death Discov

Therapeutic targeting of STING-IL6/STAT3 axis to inhibit osteoclastic niche formation and breast cancer bone metastasis. [Abstract]

2025 Oct 24;11(1):483. PMID: 41136375
Acta Pharmacol Sin

Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. [Abstract]

2021 May;42(5):814-823. PMID: 32855532
NPJ Precis Oncol

Filgotinib inhibits METTL3-mediated m6A of EIF3A by targeting ERG-TBP to suppress PDAC progression JAK-STAT3-independently. [Abstract]

2026 Apr 1;10(1):193. PMID: 41922492
Proc Natl Acad Sci U S A

A CRISPR-Cas9 knockout screening identifies IRF2 as a key driver of OAS3/RNase L-mediated RNA decay during viral infection. [Abstract]

2024 Nov 5;121(45):e2412725121. PMID: 39475651
Proc Natl Acad Sci U S A

A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives. [Abstract]

2022 Apr 12;119(15):e2122512119. PMID: 35380904

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

The induction of MIS target genes Id2, Id3, Smad6, and Igfbp5 was recapitulated as measured by qPCR following a 48 h incubation of ex vivo cultured ovaries from PND2 rat with 1 μM candidate MISR2 agonists Gandotinib, SP600125m, CYC-116, Ruxolitinib.

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

Representative DDX4 immunofluorescence following 48 h incubation of ovaries from PND2 mice cultured ex vivo with 1 μM candidate MISR2 agonists Gandotinib, SP600125, CYC-116, Ruxolitinib.
Dev Cell

MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. [Abstract]

2026 Jan 12:S1534-5807(25)00768-3. PMID: 41529690
Dev Cell

Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer. [Abstract]

2025 Aug 25:S1534-5807(25)00499-X. PMID: 40865518
Leukemia

Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model. [Abstract]

2023 May;37(5):1068-1079. PMID: 36928007
Leukemia

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. [Abstract]

2012 Oct;26(10):2233-44. PMID: 22469781
Int J Biol Macromol

Targeting JAK/STAT3 in glioblastoma cells using an alginate-PNIPAm molecularly imprinted hydrogel for the sustained release of ruxolitinib. [Abstract]

2025 Apr:298:140025. PMID: 39828178
Int J Biol Macromol

Functional analysis and regulation mechanism of interferon gamma in macrophages of large yellow croaker (Larimichthys crocea). [Abstract]

2022 Jan 1:194:153-162. PMID: 34863827
NPJ Breast Cancer

JAK/STAT1-interferon-ISGylation networks in breast cancer resistance to inhibitors of FOXM1 and CDK4/6. [Abstract]

2026 Feb 12. PMID: 41680190
Mol Med

JAK2/STAT3/HMGCS2 signaling aggravates mitochondrial dysfunction and oxidative stress in hyperuricemia-induced cardiac dysfunction. [Abstract]

2025 May 13;31(1):184. PMID: 40361044
Antioxidants (Basel)

Alpha-Lipoic Acid Inhibits IFN-γ-Induced PD-L1 Expression in Prostate Cancer Cells and Enhances T-Cell-Mediated Anti-Tumor Cytotoxicity. [Abstract]

2026 Mar 25;15(4):413. PMID: 42072056
Cell Mol Gastroenterol Hepatol

Oncostatin M induces IFITM1 expression to inhibit hepatitis B virus replication via JAK-STAT signaling. [Abstract]

2024;17(2):219-235. PMID: 37879404
Haematologica

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. [Abstract]

2020 Jan;105(1):124-135. PMID: 30948489
View

2025 Oct 28.
Free Radic Biol Med

Exosomal CagA induces macrophage polarization and ferroptosis by JAK1-2/STAT1 signaling pathway in Helicobacter pylori-associated gastritis. [Abstract]

2025 Nov:239:91-103. PMID: 40706822
EMBO Mol Med

ZNF334 truncation mutation drives cold-induced autoinflammation. [Abstract]

2025 Oct 30. PMID: 41168503
EMBO Mol Med

JAK/STAT inhibition protects glucocorticoid receptor knockout mice from lethal malaria-induced hypoglycemia and hyperinflammation. [Abstract]

2025 Aug;17(8):2040-2070. PMID: 40702267
Cancer Immunol Res

TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. [Abstract]

2025 Jan 9:OF1-OF19. PMID: 39785827
Blood Adv

Differential effects of GVHD therapies on intestinal epithelium. [Abstract]

2026 Feb 5:bloodadvances.2025017189. PMID: 41643175
Cell Rep

Autonomous STING signaling in Purkinje cells drives neurodegeneration independent of type I interferon. [Abstract]

2025 Oct 29;44(11):116480. PMID: 41166304
Blood Adv

Preclinical efficacy of tasquinimod-based combinations in advanced myeloproliferative neoplasms (MPN) in blastic phase. [Abstract]

2025 Aug 19:bloodadvances.2025016898. PMID: 40829105
Blood Adv

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. [Abstract]

2025 Jul 2:bloodadvances.2024015322. PMID: 40601898
Cell Rep

LTP expression mediated by autonomous activity of GluN2B-bound CaMKII. [Abstract]

2024 Oct 11;43(10):114866. PMID: 39395168
Cell Rep

Targeting high circDNA2v levels in colorectal cancer induces cellular senescence and elicits an anti-tumor secretome. [Abstract]

2024 Apr 23;43(4):114111. PMID: 38615319
Cell Rep

Newly synthesized AIFM1 determines the hypersensitivity of T lymphocytes to STING activation-induced cell apoptosis. [Abstract]

2023 Mar 30;42(4):112327. PMID: 37000625
Cell Rep

The Natural Compound Notopterol Binds and Targets JAK2/3 to Ameliorate Inflammation and Arthritis. [Abstract]

2020 Sep 15;32(11):108158. PMID: 32937124

Ruxolitinib purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Sep 15;32(11):108158. [Abstract]

Cxcl10 and Ccl5 mRNA levels are analyzed in TNF-α (100 ng/mL)-stimulated BMDMs for 6 h, which are pretreated with notopterol (10 mM) in the presence or absence of Ruxolitinib (10 μM) or SD1029 (10 μM) for 3 h.
Blood Adv

The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy. [Abstract]

2018 Dec 11;2(23):3428-3442. PMID: 30504235
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Genomics Proteomics Bioinformatics

CTSC-RAB38 Potentiates Responsiveness to PD-1 Blockade in Esophageal Squamous Cell Carcinoma. [Abstract]

2026 Jun 18:qzag048. PMID: 42316836
Sci Signal

2026 Jul 7;19(945):eadz7366. PMID: 42412915
Emerg Microbes Infect

NSUN2-mediated m5C methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections. [Abstract]

2023 Dec;12(1):2178238. PMID: 36748584
Cancer Cell Int

Granulocyte colony-stimulating factor potentiates all-trans retinoic acid-induced granulocytic differentiation in acute promyelocytic leukemia cell line HT93A. [Abstract]

2015 Mar 12:15:30. PMID: 25805962
PLoS Biol

CMPK2 is a host restriction factor that inhibits infection of multiple coronaviruses in a cell-intrinsic manner. [Abstract]

2023 Mar 17;21(3):e3002039. PMID: 36930652
JCI Insight

Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy. [Abstract]

2025 Jul 8;10(13):e188843. PMID: 40626363
JCI Insight

Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis. [Abstract]

2024 Dec 6;9(23):e173665. PMID: 39470742
JCI Insight

Ruxolitinib inhibits cyclosporine-induced proliferation of cutaneous squamous cell carcinoma. [Abstract]

2018 Sep 6;3(17):e120750. PMID: 30185657

Ruxolitinib purchased from MedChemExpress. Usage Cited in: JCI Insight. 2018 Sep 6;3(17):e120750. [Abstract]

A431 cells are then treated in full growth media with vehicle, CSA (50 ng/mL), Ruxolitinib (20 μM), or both Ruxolitinib and CSA for 36 hours.
Talanta

Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring. [Abstract]

2020 Feb 1:208:120450. PMID: 31816725
J Agric Food Chem

Anti-inflammatory mechanism of ginseng saponin metabolite Rh3 in lipopolysaccharide-stimulated microglia: critical role of 5'-adenosine monophosphate-activated protein kinase signaling pathway. [Abstract]

2015 Apr 8;63(13):3472-80. PMID: 25798758
CNS Neurosci Ther

Hypoxia Upregulates RIPK1 via the HIF-1α-JAK-STAT Pathway Leading to Astrocyte Necroptosis to Promote Cavitation After Spinal Cord Injury. [Abstract]

2026 May;32(5):e70895. PMID: 42109032
Biochem Pharmacol

Ferulic acid promotes thrombopoiesis via TLR4/JAK2/STAT3 signaling: A novel therapeutic strategy for thrombocytopenia. [Abstract]

2025 Sep:239:117088. PMID: 40571222
Mol Ther Nucleic Acids

Inhibition of IFNAR-JAK signaling enhances tolerability and transgene expression of systemic non-viral DNA delivery. [Abstract]

2025 Mar 5;36(2):102502. PMID: 40206655
Cell Biosci

Modaline sulfate promotes Oct4 expression and maintains self-renewal and pluripotency of stem cells through JAK/STAT3 and Wnt signaling pathways. [Abstract]

2021 Aug 4;11(1):156. PMID: 34348786
Biochem Pharmacol

Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease. [Abstract]

2020 Aug:178:114103. PMID: 32562787
Inflamm Res

Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. [Abstract]

2015 Jan;64(1):41-51. PMID: 25387665
Oncogenesis

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts. [Abstract]

2019 Feb 22;8(3):15. PMID: 30796200
Cancer Immunol Immunother

A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma. [Abstract]

2026 May 30. PMID: 42217049
Nutrients

Three Polymethoxyflavones Purified from Ougan ( Citrus reticulata Cv. Suavissima) Inhibited LPS-Induced NO Elevation in the Neuroglia BV-2 Cell Line via the JAK2/STAT3 Pathway. [Abstract]

2019 Apr 5;11(4):791. PMID: 30959824
Cancer Biol Ther

Antibody dependent cell-mediated cytotoxicity selection pressure induces diverse mechanisms of resistance. [Abstract]

2023 Dec 31;24(1):2269637. PMID: 37878417
Eur J Pharmacol

ATRA promotes PD-L1 expression to control gastric cancer immune surveillance. [Abstract]

2022 Apr 5:920:174822. PMID: 35151642
Int J Mol Sci

Identification of Novel JAK2 Inhibitors from Amino Derivatives of Epoxyalantolactone: In Silico and In Vitro Studies. [Abstract]

2025 Dec 28;27(1):329. PMID: 41516206
Int Immunopharmacol

Paeoniflorin attenuates neuropathic Pain-associated depression by modulating microglial M1 polarization and correcting kynurenine pathway dysregulation. [Abstract]

2025 Oct 30:164:115351. PMID: 40803216
Int J Mol Sci

Ruxolitinib Modulates P-Glycoprotein Function, Delays T Cell Activation, and Impairs CCL19 Chemokine-Directed Migration in Human Cytotoxic T Lymphocytes. [Abstract]

2025 Jun 26;26(13):6123. PMID: 40649901
Int Immunopharmacol

House dust mite induced mucosal barrier dysfunction and type 2 inflammatory responses via the MAPK/AP-1/IL-24 Signaling pathway in allergic rhinitis. [Abstract]

2025 Feb 20:148:113972. PMID: 39826453
Int Immunopharmacol

Atractylodin alleviates polycystic ovary syndrome by inhibiting granule cells ferroptosis through pyruvate dehydrogenase kinase 4-mediated JAK-STAT3 pathway. [Abstract]

2025 Jan 27:146:113817. PMID: 39724732
Int J Mol Sci

JAK Signaling Is Critically Important in Cytokine-Induced Viral Susceptibility of Keratinocytes. [Abstract]

2023 May 25;24(11):9243. PMID: 37298195
Int J Mol Sci

Lipid-Independent Regulation of PLIN5 via IL-6 through the JAK/STAT3 Axis in Hep3B Cells. [Abstract]

2023 Apr 13;24(8):7219. PMID: 37108378
Int Immunopharmacol

Effects of Ruxolitinib on fibrosis in preclinical models of systemic sclerosis. [Abstract]

2023 Mar:116:109723. PMID: 36696855
Int J Mol Sci

Inhibition of JAK1,2 Prevents Fibrotic Remodeling of Pulmonary Vascular Bed and Improves Outcomes in the Rat Model of Chronic Thromboembolic Pulmonary Hypertension. [Abstract]

2022 Dec 9;23(24):15646. PMID: 36555286
Int J Mol Sci

RNase 7 Inhibits Uropathogenic Escherichia coli-Induced Inflammation in Bladder Cells under a High-Glucose Environment by Regulating the JAK/STAT Signaling Pathway. [Abstract]

2022 May; 23(9): 5156. PMID: 35563546
Int J Mol Sci

In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. [Abstract]

2022 Apr 12;23(8):4277. PMID: 35457095
Inflammation

Inhibition of Mitochondrial Succinate Dehydrogenase with Dimethyl Malonate Promotes M2 Macrophage Polarization by Enhancing STAT6 Activation. [Abstract]

2025 Jan 13. PMID: 39806091
Mol Med Rep

Elevated IgG levels induce an M2‑to‑M1 phenotypic shift in mucosal macrophages and restrict the growth of invasive sphenoid sinus pituitary adenomas. [Abstract]

2026 Jun;33(6):168. PMID: 41992957
Biochim Biophys Acta Mol Basis Dis

M1 macrophages enhance breast cancer chemoresistance via JAK-STAT3 signaling. [Abstract]

2025 Sep 18;1872(1):168056. PMID: 40975142
Sci Rep

Combination of artesunate and ruxolitinib suppresses T cell leukemia/lymphoma proliferation via the JAK STAT pathway. [Abstract]

2026 Feb 11;16(1):8354. PMID: 41673103
PLoS Pathog

SAMD9L inhibits flavivirus translation independently of its capacity to trigger innate immune response. [Abstract]

2025 Dec 8;21(12):e1013773. PMID: 41359666
PLoS Pathog

Retinol binding protein 4 enhances cellular cholesterol uptake to facilitate influenza A virus infection. [Abstract]

2025 Oct 27;21(10):e1013623. PMID: 41144502
Sci Rep

Interleukin-7 enhances recruitment of MDSCs by regulating MCP-1 via JAK1/STAT3 signaling pathway in non-small cell lung cancer. [Abstract]

2025 May 15;15(1):16869. PMID: 40374882
Sci Rep

HPV16 E6-induced M2 macrophage polarization in the cervical microenvironment via exosomal miR-204-5p. [Abstract]

2024 Oct 10;14(1):23725. PMID: 39390116
Cancer Sci

Interleukin 6 regulates the expression of programmed cell death ligand 1 in thyroid cancer. [Abstract]

2021 Mar;112(3):997-1010. PMID: 33247999
Sci Rep

Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice. [Abstract]

2021 Feb 15;11(1):3847. PMID: 33589712
Cancers (Basel)

CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia. [Abstract]

2024 Apr 16;16(8):1511. PMID: 38672593
Cancers (Basel)

High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia. [Abstract]

2022 Dec 31;15(1):296. PMID: 36612292
Neuropharmacology

Cyclic neuronostatin regulates glucose homeostasis and food intake through GPR107 phosphorylation. [Abstract]

2026 May 27:111026. PMID: 42208758
Cell Signal

Paeoniflorin-6'-O-benzene sulfonate inhibits keratinocyte proliferation by restoring GRK2-JAK1 colocalization in mouse model of psoriasis. [Abstract]

2025 Jul:131:111706. PMID: 40037425
J Cell Mol Med

CD44 Participates to Extramedullary Haematopoiesis Onset by Mediating the Interplay Between Monocytes and Haematopoietic Stem Cells in Myelofibrosis. [Abstract]

2025 Jul;29(14):e70720. PMID: 40690545
Mol Cell Biochem

Amyloid beta-induced signalling in leptomeningeal cells and its impact on astrocyte response. [Abstract]

2025 Apr;480(4):2645-2660. PMID: 39499391
Oncol Rep

Cysteine‑ and glycine‑rich protein 2: A vital regulator that inhibits necroptosis glioma cell by activating the JAK‑STAT1 pathways. [Abstract]

2025 Mar;53(3):40. PMID: 39918019
Oncol Rep

Butyrate increases methylglyoxal production through regulation of the JAK2/Stat3/Nrf2/Glo1 pathway in castration‑resistant prostate cancer cells. [Abstract]

2024 May;51(5):71. PMID: 38577936
J Cell Mol Med

Penttinen syndrome-associated PDGFRB Val665Ala variant causes aberrant constitutive STAT1 signalling. [Abstract]

2022 Jul;26(14):3902-3912. PMID: 35689379
J Cell Mol Med

Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy. [Abstract]

2021 Jan;25(2):1089-1099. PMID: 33314568
Oncol Rep

Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. [Abstract]

2018 Aug;40(2):635-646. PMID: 29917168
J Inflamm Res

ZnO NPs Attenuate LPS-Induced Inflammation in RAW264.7 Macrophages by Inhibiting NF-κB and JAK1-STAT1/STAT3 Pathways and Reducing ROS. [Abstract]

2025 Oct 9:18:14075-14096. PMID: 41089401
Clin Exp Med

Bioinformatics and experimental approaches identify NME8 as a promoter of the metastasis of renal cell carcinoma by activating the JAK/STAT signaling pathway. [Abstract]

2026 Jan 2;26(1):68. PMID: 41483244
iScience

Transcriptional synergy in human aortic endothelial cells is vulnerable to combination p300/CBP and BET bromodomain inhibition. [Abstract]

2024 May 16;27(6):110011. PMID: 38868181
Biomedicines

Generation of a Pure Culture of Neuron-like Cells with a Glutamatergic Phenotype from Mouse Astrocytes. [Abstract]

2022 Apr 18;10(4):928. PMID: 35453678
iScience

Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway. [Abstract]

2021 Sep 25;24(10):103173. PMID: 34693224
Poult Sci

SC75741 antagonizes vesicular stomatitis virus, duck Tembusu virus, and duck plague virus infection in duck cells through promoting innate immune responses. [Abstract]

2021 May;100(5):101085. PMID: 33799115
Endocr Relat Cancer

Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells. [Abstract]

2023 Jul 25;30(9):e230130. PMID: 37260320
J Pharmacol Exp Ther

Enhancing local glioblastoma treatment via in vitro synergistic pairing of Janus kinase/signal transducer and activator of transcription-3 inhibitor with antiepileptic drugs. [Abstract]

2025 Oct 31;393(1):103767. PMID: 41406909
FASEB J

Baicalin Alleviates Chronic Pancreatitis Fibrosis and Islet Dysfunction via Targeting IFNAR-Mediated JAK/STAT Signaling and Immune Modulation. [Abstract]

2025 Sep 30;39(18):e71032. PMID: 40948402
FEBS J

Interferon-γ induces retinal pigment epithelial cell Ferroptosis by a JAK1-2/STAT1/SLC7A11 signaling pathway in Age-related Macular Degeneration. [Abstract]

2022 Apr;289(7):1968-1983. PMID: 34741776
J Virol

Porcine reproductive and respiratory syndrome virus N protein-mediated viral replication enhancement via interaction with host caspase-6. [Abstract]

2026 May 19;100(5):e0016326. PMID: 41979901
J Virol

Discovery and rescue of porcine bastroviruses associated with polioencephalomyelitis in domestic pigs. [Abstract]

2025 Aug 18:e0113025. PMID: 40824087
J Virol

Contrasting interferon-mediated antiviral responses in human lung adenocarcinoma cells. [Abstract]

2025 Jun 17;99(6):e0046925. PMID: 40434103
J Virol

The pseudogene GBP1P1 suppresses influenza A virus replication by acting as a protein decoy for DHX9. [Abstract]

2024 Jul 23;98(7):e0073824. PMID: 38940585
J Biol Chem

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities. [Abstract]

2015 Nov 27;290(48):29022-34. PMID: 26446793

Ruxolitinib purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34. [Abstract]

10⁶ autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an
J Biotechnol

Interferon inhibitors increase rAAV production in HEK293 cells. [Abstract]

2025 Mar:399:9-18. PMID: 39824361
PLoS Genet

Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. [Abstract]

2024 May 28;20(5):e1011293. PMID: 38805570
Clin Exp Immunol

The autoimmune encephalitis-related cytokine TSLP in the brain primes neuroinflammation by activating the JAK2-NLRP3 axis. [Abstract]

2022 Jan 28;207(1):113-122. PMID: 35020848
Cell Cycle

SCF/c-kit signaling pathway participates in ICC damage in neurogenic bladder. [Abstract]

2020 Aug;19(16):2074-2080. PMID: 32658594
J Gen Virol

In vivo inhibition of JAK-STAT signalling enhances high pathogenicity influenza virus replication in ducks. [Abstract]

2026 Mar;107(3):002238. PMID: 41770592
J Transl Autoimmun

Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation. [Abstract]

2026 Mar 23:12:100367. PMID: 41958541
Pathogens

Extracellular Lipopolysaccharide Triggers the Release of Unconjugated Interferon-Stimulated Gene 15 (ISG15) Protein from Macrophages via Type-I Interferon/Caspase-4/Gasdermin-D Pathway. [Abstract]

2026 Jan 22;15(1):122. PMID: 41599106
Metab Brain Dis

β-Caryophyllene modulates the JAK2/STAT3 signaling pathway to downregulate neutrophil extracellular traps and alleviate cerebral ischemia-reperfusion injury. [Abstract]

2025 Oct 30;40(8):301. PMID: 41165931
Neurotoxicology

In vitro cytotoxicity assessment of ruxolitinib on oligodendrocyte precursor cell and neural stem/progenitor cell populations. [Abstract]

2024 Dec:105:10-20. PMID: 39209271
Metab Brain Dis

Oncogenic role of microRNA-19b-3p-mediated SOCS3 in glioma through activation of JAK-STAT pathway. [Abstract]

2023 Mar;38(3):945-960. PMID: 36484970
J Med Virol

Revisiting the role of endogenous STAT3 in HPV-positive cervical cancer cells. [Abstract]

2023 Nov;95(11):e29230. PMID: 38009614
Blood Sci

Micheliolide exerts effects in myeloproliferative neoplasms through inhibiting STAT3/5 phosphorylation via covalent binding to STAT3/5 proteins. [Abstract]

2023 Jul 12;5(4):258-268. PMID: 37941916
ACS Chem Biol

A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. [Abstract]

2017 May 19;12(5):1245-1256. PMID: 28263556
J Leukoc Biol

Enhancing Tyro3 signaling ameliorates IL-1β production through STAT1 in Alzheimer's disease models. [Abstract]

2025 Dec 1;117(12):qiaf157. PMID: 41206011
Exp Dermatol

Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL-13. [Abstract]

2025 Jul;34(7):e70132. PMID: 40678986
Invest New Drugs

Combination of ruxolitinib with ABT-737 exhibits synergistic effects in cells carrying concurrent JAK2V617F and ASXL1 mutations. [Abstract]

2022 Dec;40(6):1194-1205. PMID: 36044173
J Leukoc Biol

HIV-1-induced type I IFNs promote viral latency in macrophages. [Abstract]

2022 Nov;112(5):1343-1356. PMID: 35588262
Front Oncol

CXCL10 Produced by HPV-Positive Cervical Cancer Cells Stimulates Exosomal PDL1 Expression by Fibroblasts via CXCR3 and JAK-STAT Pathways. [Abstract]

2021 Aug 6:11:629350. PMID: 34422627
Neuroscience

Oncostatin-M-Reactive Pericytes Aggravate Blood-Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro. [Abstract]

2019 Dec 1:422:12-20. PMID: 31705893
J Immunol Res

2026 Jul 1;2026(1):1427790.
Mol Biol Rep

Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1. [Abstract]

2024 Jul 22;51(1):832. PMID: 39037638
Mol Biol Rep

Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line. [Abstract]

2023 Jan;50(1):319-329. PMID: 36331743
Int J Med Microbiol

Testosterone regulates the intracellular bacterial community formation of uropathogenic Escherichia coli in prostate cells via STAT3. [Abstract]

2020 Oct;310(7):151450. PMID: 33092696
Kaohsiung J Med Sci

Exosomal circNFIX promotes angiogenesis in ovarian cancer via miR-518a-3p/TRIM44 axis. [Abstract]

2023 Jan;39(1):26-39. PMID: 36448712
Exp Eye Res

GSDMD, an executor of pyroptosis, is involved in IL-1β secretion in Aspergillus fumigatus keratitis. [Abstract]

2021 Jan:202:108375. PMID: 33279525
AIDS

Interferon-induced sterile alpha motif and histidine/aspartic acid domain-containing protein 1 expression in astrocytes and microglia is mediated by microRNA-181a. [Abstract]

2016 Aug 24;30(13):2053-64. PMID: 27219130
Vet Microbiol

Long noncoding RNA USP30-AS1 promotes influenza A virus replication by enhancing PHB1 function. [Abstract]

2025 Apr:303:110444. PMID: 40020267
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
Vet Microbiol

IFIT3 mediated the type I interferon antiviral response by targeting Senecavirus A entry, assembly and release pathways. [Abstract]

2022 Dec:275:109594. PMID: 36332300
PLoS One

A transcriptomic analysis of the effects of macrophage polarization and endotoxin tolerance on the response to Salmonella. [Abstract]

2022 Oct 14;17(10):e0276010. PMID: 36240188
PLoS One

Analysis of acute lymphoblastic leukemia drug sensitivity by changes in impedance via stromal cell adherence. [Abstract]

2021 Sep 30;16(9):e0258140. PMID: 34591931
Clin Exp Dermatol

Downregulation of SHANK-associated RH domain-interacting protein elevates interleukin-33 expression by stimulating the Janus kinase 2/signal transducer and activator of transcription signalling pathway in HaCaT cells. [Abstract]

2021 Jul;46(5):880-887. PMID: 33548083
PLoS One

Testosterone suppresses uropathogenic Escherichia coli invasion and colonization within prostate cells and inhibits inflammatory responses through JAK/STAT-1 signaling pathway. [Abstract]

2017 Jun 30;12(6):e0180244. PMID: 28665978
Chem Pap

2026 Feb 14.
Exp Hematol

Ruxolitinib ameliorates progressive anemia and improves survival during episodes of emergency granulopoiesis in Fanconi C-/- mice. [Abstract]

2022 May:109:55-67.e2. PMID: 35278531
Fundam Clin Pharmacol

Inhibition of organic cation transporter 3 activity by tyrosine kinase inhibitors. [Abstract]

2021 Oct;35(5):919-929. PMID: 33523504
J Mol Histol

Echinacoside ameliorates bleomycin-induced idiopathic pulmonary fibrosis by regulating macrophage polarization. [Abstract]

2025 Nov 24;57(1):4. PMID: 41284091
Virology

IFIT3 inhibits transmissible gastroenteritis virus (TGEV) infection by promoting the phosphorylation of TBK1 and STAT1, which enhances the innate immune response. [Abstract]

2025 Aug:609:110574. PMID: 40381424
Anim Reprod Sci

Differential impact of the kinase inhibitors ruxolitinib and ceritinib on porcine sperm in vitro. [Abstract]

2025 Jun:277:107850. PMID: 40318512
Virology

Long non-coding RNA SUN2-AS1 acts as a negative regulator of ISGs transcription to promote flavivirus infection. [Abstract]

2024 Dec:600:110245. PMID: 39288611
Eur J Haematol

Interferon gamma regulates a complex pro-survival signal network in chronic lymphocytic leukemia. [Abstract]

2023 Apr;110(4):435-443. PMID: 36576398
Clin Cosmet Investig Dermatol

IL-4, IL-13, TNF-α and IFN-γ Downregulate CLDN8 Expression Through Activating JAK Signaling Pathway in HaCaT Cells. [Abstract]

2025 Apr 24:18:999-1009. PMID: 40296865
Biochem Biophys Res Commun

Upregulation of IL-4 signaling contributes to aerobic exercise-induced insulin sensitivity. [Abstract]

2020 May 7;525(3):662-667. PMID: 32127173
Eur J Drug Metab Pharmacokinet

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors. [Abstract]

2021 Sep;46(5):625-635. PMID: 34275128
Mol Genet Genomics

P2RX1 in neutrophils mediates JAK/STAT signaling pathway to regulate malignant phenotype of gastric Cancer cells. [Abstract]

2025 Feb 22;300(1):23. PMID: 39985719
Cytojournal

Association of immunosuppressive CD45+CD33+CD14- CD10-HLA-DR-/low neutrophils with poor prognosis in patients with lymphoma and their expansion and activation through STAT3/arginase-1 pathway in vitro. [Abstract]

2024 Dec 20:21:69. PMID: 39916996
Leuk Lymphoma

IFN-γ enhances CLL cell resistance to ABT-199 by regulating MCL-1 and BCL-2 expression via the JAK-STAT3 signaling pathway. [Abstract]

2023 Jan;64(1):71-78. PMID: 36222521
J Vet Sci

Role of IFNLR1 gene in PRRSV infection of PAM cells. [Abstract]

2021 May;22(3):e39. PMID: 34056880
J Physiol Investig

Mechanism of Action of Exercise in Regulating Spontaneous Hypertension through the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway. [Abstract]

2025 Mar 31. PMID: 40170455
Tohoku J Exp Med

SALL4 Transcriptional Regulates CRIPTO to Boost the Stemness and Doxorubicin Hydrochloride Resistance of Colon Cancer Cells. [Abstract]

2026 Apr 9. PMID: 41951377
STAR Protoc

Protocol for generating megakaryocytes from patient induced pluripotent stem cells for disease modeling and compound screening. [Abstract]

2026 Feb 26;7(1):104393. PMID: 41762654
Mol Cell Toxicol

2026 Jan 22.
Int J Clin Exp Pathol

2017;10(3):3033-3042.
Technical University of Braunschweig

2026.
Res Sq

2026 Jun 1.
bioRxiv

2026 May 12.
bioRxiv

2026 May 8.
Karolinska Institutet

2026 Apr 27.
Res Sq

2026 Apr 13.
bioRxiv

2026 Mar 7.
bioRxiv

2026 Feb 26.
bioRxiv

2026 Jan 13.
bioRxiv

2026 Jan 23.
bioRxiv

2026 Jan 8.
bioRxiv

2025 Nov 30.
bioRxiv

Single-cell heterogeneity in interferon induction potential is heritable and governed by variation in cell state. [Abstract]

2025 Dec 22:2025.12.09.693293. PMID: 41415397
bioRxiv

Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. [Abstract]

2025 Nov 20:2025.11.19.689204. PMID: 41332750
bioRxiv

JAK1/2 Inhibition Delays Cachexia and Improves Survival through Increased Food Intake. [Abstract]

2025 Oct 22:2025.10.21.683287. PMID: 41278737
bioRxiv

2025 Sep 21.
University of Pennsylvania

2025.
Res Sq

2025 Sep 25.
bioRxiv

DFFB suppresses interferon to enable cancer persister cell regrowth. [Abstract]

2025 Aug 21:2025.08.15.670603. PMID: 40894800
SSRN

2025 Jul 26.
bioRxiv

Tendon fibroblast inflammatory responses depend on NF-κβ and JAK/STAT signaling and alter mechanotransduction pathways. [Abstract]

2025 Jul 8:2025.07.04.663209. PMID: 40672276
Patent

US20250228857A1.
bioRxiv

2025 June 03.
bioRxiv

Global Landscape of Human Kinase Motifs in Viral Proteomes. [Abstract]

2025 Jun 3:2025.06.02.657064. PMID: 40502089
Pennsylvania State University

2025.
Preprints

2025 May 08.
University of Washington

2025.
Res Sq

2025 Apr 14.
bioRxiv

Antigenic cancer persister cells survive direct T cell attack. [Abstract]

2025 Mar 17:2025.03.14.643359. PMID: 40166148
SSRN

2025 Feb 11.
bioRxiv

2025 February 21.
Neuroscience Research Notes

2025 Feb 02.
bioRxiv

2025 January 31.
bioRxiv

Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy. [Abstract]

2024 Dec 3:2024.11.27.625710. PMID: 39677814
University of Düsseldorf

2024.
Harvard University

2024 May.
bioRxiv

TBK1 and IKKε protect target cells from IFNγ-mediated T cell killing via an inflammatory apoptotic mechanism. [Abstract]

2024 Aug 8:2024.08.06.606693. PMID: 39149268
Columbia University

2024.
Res Sq

2024 Jun 13.
Université de Lausanne

2024 Feb 7.
Research Square Preprint

2023 Sep 11.
Biomed Pharmacother

Guiqi Baizhu prescription ameliorates cytarabine-induced intestinal mucositis by targeting JAK2 to inhibit M1 macrophage polarization. [Abstract]

2023 Aug:164:114902. PMID: 37209628
Ruperto Carola University Heidelberg

2023 Jun 1.
bioRxiv

Sexual dimorphism in melanocyte stem cell behavior reveals combinational therapeutic strategies for cutaneous repigmentation. [Abstract]

2023 May 22:2023.05.22.541644. PMID: 37293072
Patent

US20220305048A1.
University of Michigan

2022 Aug.
Research Square Print

August 22nd, 2022.
University of Zürich

2021 Dec.
bioRxiv

2021 Feb 5.
Patent

US20210025893A1.
Chemosphere

Effects of cyhalofop-butyl on the developmental toxicity and immunotoxicity in zebrafish (Danio rerio). [Abstract]

2021 Jan:263:127849. PMID: 33297003
Patent

US20180263995A1.
Harvard Medical School

2018 June 13.
Oncotarget

Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice. [Abstract]

2017 Oct 4;8(55):94040-94053. PMID: 29212208

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (326.40 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.2640 mL

16.3201 mL

32.6403 mL

5 mM

0.6528 mL

3.2640 mL

6.5281 mL

10 mM

0.3264 mL

1.6320 mL

3.2640 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (6.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (6.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (6.79 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

All Cell Biology Signal Pathway Related

Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
Mitophagy Solutions
Mitophagy is the selective autophagic degradation of mitochondria and functions as a mitochondrial quality-control pathway that removes damaged, depolarized, excess, or developmentally programmed mitochondria. The pathway links mitochondrial damage recognition, autophagosome recruitment, lysosomal delivery, and mitochondrial turnover to phenotypes such as mitochondrial homeostasis, oxidative-stress control, metabolic remodeling, differentiation, and neurodegeneration-related mitochondrial fidelity. The best-characterized damage-induced pathway is the PINK1-Parkin axis. Parkin is recruited selectively to impaired mitochondria and promotes their autophagic elimination, while mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, recruits Parkin, and activates Parkin-dependent mitophagy. PINK1 also phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity, and PINK1-driven ubiquitin phosphorylation creates a feed-forward signal for recruiting autophagy machi
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
Directly Induced Neuron Culture
Directly induced neuron culture converts somatic cells, most commonly fibroblasts, into induced neurons without passing through a pluripotent or neural progenitor stage; classic evidence shows that mouse fibroblasts can be converted by Ascl1, Brn2/Pou3f2, and Myt1l, human fibroblasts can be converted by defined neuronal transcription factors, and human fibroblasts can also be converted by miR-9/9-124 with neurogenic or subtype-specifying transcription factors. The readout is acquisition of neuronal identity and function, assessed by neuronal morphology, neuronal markers such as Tuj1/βIII-tubulin, MAP2, synapsin, and subtype markers when relevant, together with functional assays such as action-potential firing, synaptic activity, and electrophysiology.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Korean - KR (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Quintas-Cardama A, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117. [Content Brief]

[2]. Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med, 2012, 366(9), 799-807. [Content Brief]

[3]. Tavallai M, et al. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.Front Oncol. 2016 Jun 13;6:142. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.2640 mL	16.3201 mL	32.6403 mL	81.6007 mL
	5 mM	0.6528 mL	3.2640 mL	6.5281 mL	16.3201 mL
	10 mM	0.3264 mL	1.6320 mL	3.2640 mL	8.1601 mL
	15 mM	0.2176 mL	1.0880 mL	2.1760 mL	5.4400 mL
	20 mM	0.1632 mL	0.8160 mL	1.6320 mL	4.0800 mL
	25 mM	0.1306 mL	0.6528 mL	1.3056 mL	3.2640 mL
	30 mM	0.1088 mL	0.5440 mL	1.0880 mL	2.7200 mL
	40 mM	0.0816 mL	0.4080 mL	0.8160 mL	2.0400 mL
	50 mM	0.0653 mL	0.3264 mL	0.6528 mL	1.6320 mL
	60 mM	0.0544 mL	0.2720 mL	0.5440 mL	1.3600 mL
	80 mM	0.0408 mL	0.2040 mL	0.4080 mL	1.0200 mL
	100 mM	0.0326 mL	0.1632 mL	0.3264 mL	0.8160 mL

Bioz

Keywords

Ruxolitinib

281 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ruxolitinib

Publications Citing Use of MedChemExpress (MCE) Ruxolitinib

Voir tous les produits spécifiques à Isoform JAK